Intrinsic Value of S&P & Nasdaq Contact Us
English English 中文(简) 中文(简) 中文(繁) 中文(繁) हिन्दी हिन्दी Español Español 日本語 日本語 한국어 한국어 Deutsch Deutsch Français Français
← Back to all stocks

Algernon Pharmaceuticals Inc. AGNPF OTC

Other OTC • Healthcare • Biotechnology • CA • USD

SharesGrow Score
23/100
0/4 Pass
SharesGrow Intrinsic Value
N/A
Negative cash flow

Algernon Pharmaceuticals Inc. (AGNPF) is a Biotechnology company in the Healthcare sector, currently trading at $0.04. It has a SharesGrow Score of 21/100, indicating a weak investment profile with 0 out of 7 criteria passed.

Net income is $2M (loss), growing at -53.5%/yr. Net profit margin is 0% (thin). Gross margin is 0% (+0 pp trend).

Balance sheet: total debt is $0 against $3M equity (Debt-to-Equity (D/E) ratio 0, conservative). Current ratio is 0.25 (tight liquidity). Debt-to-assets is 0%. Total assets: $5M.

SharesGrow 7-Criteria breakdown: Value ?/100 (Fail), Growth 15/100 (Fail), Past 0/100 (Fail), Health 50/100 (Partial), Moat 28/100 (Fail), Future ?/100 (Fail), Income ?/100 (Fail).

AGNPF SharesGrow Score Overview

31/100
SharesGrow Score
Below average — proceed with caution
View full scorecard →
VALUE 0/100
Valuation — P/E, PEG, Forward PEG
GROWTH 15/100
Financials — average growth
PAST 0/100
strong — trend
HEALTH 50/100
Balance sheet — Debt-to-Equity (D/E) ratio, Current ratio is
MOAT 28/100
Gross margin is + market cap
FUTURE 0/100
Analyst outlook — as buy
INCOME 0/100
Net profit margin is
Scores derived from financial statements, analyst ratings, and balance sheet data.

Score Breakdown — AGNPF

—
VALUE N/A
N/A
No analyst coverage available for this stock.
✗
GROWTH Fail
15/100
AGNPF: +0%/yr revenue is, -53.5%/yr Net income is average growth. weak. Score: >20%/yr = 100, >10% = 80, >5% = 65, >0% = 45, < 0 = 15.
View details →
—
PAST N/A
N/A
No analyst coverage available for this stock.
~
HEALTH Partial
50/100
Balance sheet AGNPF: Debt-to-Equity (D/E) ratio 0 (conservative), Current ratio is 0.25 (tight liquidity). Debt-to-Equity < 0.5, Current Ratio > 1.5, Interest Coverage > 8x = ideal. ≥ 70 = Pass.
View details →
✗
MOAT Fail
28/100
AGNPF: Gross margin is 0% (+0 pp trend), N/A market cap. Moat (0-100): margin (35%) + trend (15%) + market cap (30%) + revenue is (20%). Score 28/100. ≥ 70 = Pass.
View details →
—
FUTURE N/A
N/A
No analyst coverage available for this stock.
—
INCOME N/A
N/A
No analyst coverage available for this stock.

Stock Chart & Stats

Market Data
52-Week Range0.023-0.0719
Volume2.5K
Avg Volume (30D)5.42K
Market Cap$1.25M
Beta (1Y)0.89
Share Statistics
EPS (TTM)-0.06
Shares Outstanding$29.49M
IPO Date2016-03-11
CEOChristopher J. Moreau
Financial Highlights & Ratios
Gross Profit$-54.65K
EBITDA$-1.95M
Net Income$-1.72M
Operating Income$-1.72M
Total Cash$176.38K
Net Debt$-176.38K
Total Assets$4.87M
Price / Earnings (P/E)-0.6
Analyst Forecast
Company Info
CountryCA
ExchangeOther OTC
CurrencyUSD
ISINCA01559C1068

Price Chart

Track all markets on TradingView
AGNPF
Algernon Pharmaceuticals Inc. ↗  ·  Other OTC
Healthcare • Biotechnology
0.02 52WK RANGE 0.07

People Also View

ASCLF
ASCLF
Ascletis Pharma Inc.
$2.10
+0.00%
 GHRS
GHRS
GH Research PLC
$17.00
+1.37%
 CMVLF
CMVLF
Cellectis S.A.
$3.08
-30.00%
 CVALF
CVALF
Covalon Technologies Ltd.
$1.44
-0.69%
 DMTTF
DMTTF
Small Pharma Inc.
$0.11
-9.69%
 BITRF
BITRF
Biotron Limited
$0.03
+0.00%
 RVXCF
RVXCF
Resverlogix Corp.
$0.08
-1.14%
 CRPOF
CRPOF
Ceapro Inc.
$0.17
-13.04%
Contact Us
🎓
SharesGrow Academy
Learn how to calculate Intrinsic Value and find undervalued stocks.
Weekly live sessions
📧 [email protected]
📞 +65 8912 8000
Send us a message